ENVOYER
Live / Registered — Registered (as of 06 Jan 2026)
What this means for you
Registered since 06 Jan 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98376228
- Registration number
- 8096742
- Mark type
- Stylized text
- Filed
- 25 Jan 2024
- Published for opposition
- 12 Nov 2024
- Registered
- 06 Jan 2026
- Attorney of record
- Susan G. L. Glovsky
Goods and services
- Class 005 — Pharmaceuticals: Gene therapy products, namely, non-lipid polymer based nanoparticles for gene therapy; gene therapy products, namely polymer-based nanoparticles for medical, veterinary and pharmaceutical purposes; nucleic acid-containing products, namely RNA and DNA, for medical or veterinary purposes; gene therapy products for the treatment of cancer, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, or inflammatory diseases or disorders, namely, non-viral vectors; nanoparticle products for medical or veterinary purposes, namely, non-viral vectors; nanoparticles for medical or veterinary purposes, namely, stabilized non-lipid polymer based nanoparticles; nanoparticles that encapsulate nucleic acids for medical or veterinary purposes; nanoparticles that encapsulate cytotoxic payloads in cells for medical or veterinary purposes
- Class 042 — Scientific and technological services: Pharmaceutical research and development; research and development services in the field of pharmaceuticals; gene therapy research and development services; research and development services relating to the delivery of RNA and DNA therapeutics to patients; research and development services in the field of nanoparticles and microparticles; research and development services in the field of nucleic acid-containing particles; research and development services in the field of nucleic acids, proteins, and small molecules delivery; Development of nucleic acids, namely RNA and DNA, for encapsulating nanoparticles for targeted delivery; Research services in the field of nanoparticle characteristics; Research services in the field of microparticle characteristics; research and development services in the field of pharmaceutical preparations for the treatment of disease or disorders; research and development services in the field of pharmaceutical preparations for the treatment of cancer, muscular dystrophy, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, inflammatory diseases or disorders, rare diseases; scientific and technological services, namely, scientific research, analysis, testing, treatment optimizations in the field of nucleic acids, proteins, and small molecules delivery to human cells; scientific and technological services, namely, scientific research, analysis, testing, treatment optimizations in the field of protein delivery to human cells; Scientific and technological services, namely, research and design relating to scientific and technological services in the field of nucleic acids, proteins, and small molecules therapeutics
Owner
- Envoya Inc., Brookline, MA, US
- Envoya Inc., Brookline, MA, US
- Envoya Inc., Brookline, MA, US
Prosecution history
- 06 Jan 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 06 Jan 2026 — REGISTERED-PRINCIPAL REGISTER
- 15 Dec 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 15 Dec 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 11 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Dec 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 15 Apr 2025 — USE AMENDMENT FILED
- 10 Dec 2025 — SOU EXTENSION 1 GRANTED
- 24 Jun 2025 — SOU EXTENSION 1 FILED
- 10 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 25 Aug 2025 — ASSIGNED TO EXAMINER
- 24 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Apr 2025 — TEAS STATEMENT OF USE RECEIVED
- 24 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 12 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED